Article ; Online: Auranofin Resistance in
Frontiers in cellular and infection microbiology
2021 Volume 11, Page(s) 618994
Abstract: Auranofin, a reprofiled FDA-approved drug originally designed to treat rheumatoid arthritis, has emerged as a promising anti-parasitic drug. It induces the accumulation of reactive oxygen species (ROS) in parasites, ... ...
Abstract | Auranofin, a reprofiled FDA-approved drug originally designed to treat rheumatoid arthritis, has emerged as a promising anti-parasitic drug. It induces the accumulation of reactive oxygen species (ROS) in parasites, including |
---|---|
MeSH term(s) | Animals ; Auranofin/pharmacology ; Parasites ; Reactive Oxygen Species ; Thioredoxin-Disulfide Reductase/genetics ; Toxoplasma/genetics |
Chemical Substances | Reactive Oxygen Species ; Auranofin (3H04W2810V) ; Thioredoxin-Disulfide Reductase (EC 1.8.1.9) |
Language | English |
Publishing date | 2021-03-19 |
Publishing country | Switzerland |
Document type | Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't |
ZDB-ID | 2619676-1 |
ISSN | 2235-2988 ; 2235-2988 |
ISSN (online) | 2235-2988 |
ISSN | 2235-2988 |
DOI | 10.3389/fcimb.2021.618994 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.